Exelixis, Inc. (EXEL): Lance Willsey , director of Exelixis, Inc. purchased 60,000 shares on May 9, 2016. The Insider buying transaction was reported by the company on May 11, 2016 to the Securities and Exchange Commission. The shares were purchased at $4.96 per share for a total value of $297,900.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 11, 2015, Lance Willsey (director) purchased 100,000 shares at $4.89 per share price.On Oct 19, 2015, Peter Lamb (EVP, Discovery Research & CSO) sold 51,549 shares at $5.80 per share price.
Exelixis: On Tuesday, May 10, 2016 heightened volatility was witnessed in Exelixis which led to swings in the share price. The shares opened for trading at $5 and hit $5.1 on the upside , eventually ending the session at $5.04, with a gain of 1.82% or 0.09 points. The heightened volatility saw the trading volume jump to 47,25,447 shares. The 52-week high of the share price is $6.805 and the company has a market cap of $1,153 M . The 52-week low of the share price is at $3.04.
Company has been under the radar of several Street Analysts.Exelixis is Reiterated by Stifel to Buy and the brokerage firm has raised the Price Target to $ 8 from a previous price target of $7 .The Rating was issued on Apr 26, 2016.Exelixis is Upgraded by Stifel to Buy and the brokerage firm has set the Price Target at $7. Earlier the firm had a rating of Hold on the company shares. The Rating was issued on Apr 4, 2016.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive metastatic medullary thyroid cancer (MTC) in the United States. The Company’s other programs include metastatic renal cell carcinoma (mRCC) a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888 a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).